Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 19/10/2017
SIETES contiene 92082 citas

 1 a 20 de 1377 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Gicquel C, Moulis F, Chenaf C, Gouraud A, Drici M, Bondon-Guitton E, Montastruc F, Montastruc J-L. Duloxetine and gingival bleeding: a case-report and reviews of the French and world Pharmacovigilance databases and literature. Eur J Clin Pharmacol 2017;73:1197-8. [Ref.ID 102026]
2. Cita con resumen
Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]
3. Cita con resumen
Goldacre B. The WHO joint statement from funders on trials transparency. BMJ 2017;357:j2816. [Ref.ID 101660]
4. Cita con resumen
Anónimo. WHO’s travel expenses exceed what it spends on some diseases. DIA Daily 2017:1. [Ref.ID 101587]
5.Enlace a cita original Cita con resumen
Monaco L, Biagi C, Conti V, Melis M, Donati M, Venegoni M, Vaccheri A, Motola D. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol 2017;83:1532-43. [Ref.ID 101351]
7. Cita con resumen
Schroeder LF, Guarner J, Eibireer A, Castle PE, Amukele TK. Time for a model list of essential diagnostics. N Engl J Med 2016;374:2511-4. [Ref.ID 100451]
8. Cita con resumen
Gulland A. WHO open to “lobbying” by business. BMJ 2016;353:i3134. [Ref.ID 100381]
9. Cita con resumen
Alpern JD, Song J, Stauffer WM. Essential medicines in the United States - Why access is diminishing. N Engl J Med 2016;374:1904-7. [Ref.ID 100324]
10. Cita con resumen
Ballantyne JC, Kalso E, Stannard C. WHO analgesic ladder: a good concept gone astray. BMJ 2016;352:i20. [Ref.ID 99966]
11.Tiene citas relacionadas Cita con resumen
Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, Sethi R, Takane M, Mohanty L, Chatterjee A, John TJ, Jafari H, Aylward RB. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention. an open-label, randomised controlled trial. Lancet 2015;386:2413-21. [Ref.ID 99767]
12.Tiene citas relacionadas Cita con resumen
Garon JR, Orenstein WA. A worldwide shift in polio vaccines for routine immunisation. Lancet 2015;386:2375-7. [Ref.ID 99752]
13. Cita con resumen
Anónimo. India adds 28 new drugs to essential medicines list. DIA Daily 2015:28 de diciembre. [Ref.ID 99744]
14. Cita con resumen
Maurice J. And then there were two…polio-endemic countries. Lancet 2015;386:1521-2. [Ref.ID 99659]
15. Cita con resumen
Gray AL, Wirtz VJ, 't Hoen EFM, Reich MR, Hogerzeil HV. Essential medicines are still essential. Lancet 2015;386:1601-3. [Ref.ID 99632]
16. Cita con resumen
Viola E, Pittoni AC, Drahos A, Moretti U, Conforti A. Photosensitivity with angiotensin II receptor blockers: a retrospective study using data from VigiBase. Drug Saf 2015;38:889-94. [Ref.ID 99615]
17. Cita con resumen
Allen K, Pearson-Stuttard J, Hooton W, Diggle P, Capewell S, O’Flaherty M. Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. BMJ 2015;351:h4583. [Ref.ID 99541]
18. Cita con resumen
Liakoni E, Bravo AER, Krähenbühl S. Hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf 2015;38:711-20. [Ref.ID 99478]
19. Cita con resumen
Anónimo. Rivaroxaban: atteintes hépatiques. Prescrire 2015;35:432. [Ref.ID 99428]
20. Cita con resumen
Anónimo. Paying a high price for cancer drugs. Lancet 2015;386:404. [Ref.ID 99395]
Seleccionar todas
 1 a 20 de 1377 siguiente >>